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LIST OF ABBREVIATIONS:
CK - “cysteine knot” domain
dsRNA - double stranded RNA
ER - Endoplasmic Reticulum
FVIII - factor VIII
HMWM - high molecular weight multimer
LMWM - low molecular weight multimer
PC - pachyonychia congenita
PCR - polymerase chain reaction
pDEL - (pP1105_C1926delinsR) expression vector for the deleted VWF
pDEL/C2773R - expression vector for the double mutant VWF
pWT - (pSVHVWF) expression vector for wild type VWF (with mutated SacI 
restriction site at position 8876)
RISC - RNA-induced silencing complex
RNAi - RNA interference
RT - reverse transcription
shRNA - short hairpin RNA
siRNA - short interfering RNA
TTP - thrombotic thrombocitopenic purpura
UTR - untranslated region
WPB - Weibel-Palade body
VWD - von Willebrand diseases
VWF - von Willebrand factor
VWF:Ag - von Willebrand factor antigen assay
VWF:CB - von Willebrand factor collagen-binding activity
wt - wild type
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VON WILLEBRAND FACTOR IN HAEMOSTASIS AND COAGULATION
Haemostasis is a tightly  regulated and dynamic process that maintains the 
integrity of the mammalian circulatory system under normal conditions. The 
ultimate goal is to maintain the blood in a fluid state within the vascular 
compartment but allowing it to coagulate in case of trauma. It refers to the 
complex interaction between vessels, blood cells, coagulation factors, 
coagulation inhibitors and fibrinolytic proteins. 
In the resting state the integrity of blood vessels allows endothelial cells to 
inhibit platelet adhesion/activation and thus blood coagulationʼs starting. In 
addition, the synthesis of anticoagulant proteins (as activated protein C) 
was continuously promoted by the presence of basal levels of procoagulant 
molecules: the maintenance of this equilibrium prevent clots formation1.  
After vessel injury, the balance between these processes is disturbed, and 
quick, localized and subtle regulated events occur to restore the 
equilibrium.
Figure 1: Schematic overview representation of processes that occur after 
vessel injury, in which VWF is actively involved.
First, vasoconstriction narrows the blood vessel thereby minimizing the 
vessel diameter and slowing bleeding.
Damaged endothelial cells display  negatively  charged phospholipids and 
release procoagulant proteins2, underlying tissue exposes collagen 
allowing platelets to adhere and aggregate in the primary hemostatic plug 
that temporary  blocks blood loss3. Consequently  platelet were made active 
and the coagulation cascade is initiated and amplified at each step finally 
producing fibrin, which is responsible of the platelet plug stabilization4. 
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After vessel repair, fibrinolysis results in fibrin, and thus clot, 
dissolvement5,6.
In these regulated series of events, a major role is held by VWF. This 
multimeric glycoprotein circulates in plasma in a globular, inactive state but, 
at site of  vascular injury, the high shear stress and subendothelial matrix 
exposition convert VWF into its active conformation, which allows platelet 
adhesion and aggregation. Since platelets are unable to bind to matrix 
components in high shear stress condition in the absence of VWF7, the 
bridge-function of VWF is essential for the platelet plug formation.
Figure 2: Easy description of major roles of VWF in platelet plug formation. 
First (left) VWF binds to sub-endothelial collagen exposed after vessel 
injury and allow platelet rolling and adhesion. Subsequently VWF allow 
platelet aggregation (right) and thrombus formation.
The VWF carries another important function, related to the maintenance of 
the haemostasis, as carrier of FVIII8-10 that is an important and essential 
factor involved in the coagulation cascade11. VWF-FVIII complex formation 
prevents premature clearance of FVIII from circulation11,12.
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VON WILLEBRAND FACTOR: BIOSYNTHESIS & STRUCTURE
VWF is synthesized by endothelial cells and megakaryocytes13,14. 
VWF gene (178 kb) is located on the short arm of  chromosome 12 
(12p13.3)7,15,16 and a not functional pseudogene (21-29 kbp) partially 
overlapping with full-length gene (exons 23-34) is situated on chromosome 
22g11.117,18.
The primary mRNA (9 kb) product (52 exons) is first translated in a single 
pre-pro-polypeptide chain of 2813 amino acids and include a signal peptide 
(22 residues), a large pro-peptide (741 residues) and the mature subunit of 
2050 residues (Figure 3). Almost entire pro-protein (>90%) has highly 
repetitive structure and is composed of  four types (A-D) of  repeated 
domains shared with others proteins (integrins, components of the 
complement system, thrombospondin and collagens). These motifs are 
arranged in the sequence: D1-D2-D’-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-
CK7.
Figure 3: Schematic representation of the pre-pro-VWF domain 
organization. Scissors indicate sites where VWF is cleaved during 
synthesis (before Ala23-signal peptidase site of cleavage- and Ser764 -
furin site of cleavage-) or in plasma in the A2 domain (after Tyr1605 -
ADAMTS-13 site of cleavage-). The diagram is not on scale.
It is remarkable that 234 residues (8.3%) of  the preproVWF are cysteine, 
which are abundantly clustered in the amino and carboxyl terminal region 
and rare in the A motifs. In the secreted VWF all Cys are paired in intra- or 
inter-molecular disulfide bonds. 
The mature subunit is extensively glycosylated (12 N-linked and 10 O-
linked oligosaccharides)7. 
Formation of large VWF multimers is a complex and thinly regulated series 
of events (Figure 4).
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Figure 4: Schematic representation reported by Wagner DD et al19 that 
indicate the biosynthetic steps of VWF synthesis and the cellular 
compartment where they occur.
After removal of the signal peptide by a signal peptidase, proVWF is 
translocated to the endoplasmic reticulum (ER) where it undergoes initial N-
linked glycosylation and dimerization19 (Figure 5). This event occurs 
through disulfide bond formation between C-terminal “Cysteine Knot” (CK) 
domain7,20-22. It has been demonstrated that mutations in the Cys2773 
(within sequence Cys2771-Ser-Cys-Cys2774) abrogate dimerization23 and 
subsequent studies indicate that this residue is involved in the inter-chain 
disulfide bond with the corresponding residue in a second subunit24. 
ProVWF dimers are then transported to the Golgi apparatus where N-linked 
glycosylation is completed and O-linked glycosylation is applied25 (these 
modifications add 19% to the weight of  the protein)26-28. Moving to the trans 
Golgi network, the furin-mediated29-32 pro-peptide (D1-D2 domains) 
cleavage occurs and, consequently, facilitate the multimerization through 
D’D3 amino-terminal regions of dimers33,34. Multimers, which can rinse 
20000 kDa, are designated to constitutive secretion (≃ 95%) or to storage 
in specialized cellular compartment as rod-shaped Weibel-Palade body 
(WPB) in endothelial cells and α-granules in platelets35-37 (Figure 5-6).
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Figure 5: Schematic representation of the processing steps involved in the 
biosynthesis of von Willebrand factor. ✭= non-covalent interaction; S = 
disulphide bonds. The molecular mass of the different VWF species is 
given on the right38,39.
WPBs appear to be composed by longitudinally oriented tubules 
surrounded by a membrane and multimerization itself is considered the 
triggering event for WPB-granules formation40. The largest polymers, i.e. 
ultra-large multimers, are internalized and VWF secretion from these 
storage dispenses are related to secretagogues stimuli. Sorting from 
granules requires the pro-peptide that function as catalyst in 
multimerization and as a molecular chaperone in translocation to storage 
granules. The stoichiometry of the pro-peptide and mature VWF in WPB is 
1:119,41,42. The release of  these forms of VWF at sites of  vascular damage 
would deliver the most thrombogenic molecules directly where needed.
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Figure 6: Partitioning of VWF propeptide and pro-VWF between the 
constitutive and regulated secretory pathway by vascular endothelial cells. 
The pro-VWF molecule is processed in the trans-Golgi network and results 
in heterogenous forms of VWF, ranging from dimers to large polymers. The 
largest species, consisting of partially processed and immature VWF, is 
secreted through the constitutive pathway. The remainder, largest, fully 
processed and functional VWF, is sorted into the Weibel-Palade bodies and 
secreted via the regulated pathway. This model proposes that the majority 
of VWF is secreted through the constitutive pathway38,39. 
In vivo, VWF and pro-peptide plasma levels are 10 and 1 µg/ml, with 12 h 
and 2 h half-life, respectively. About 66% of total variation in plasma VWF 
levels is genetically determined and approximately 30% of this genetic 
component can be explained by ABO blood group. Average VWF plasma 
levels for persons carrying blood group O are 25% to 35% below  that of 
persons with other blood groups43-47.
When secreted in blood flow, VWF multimer size is well regulated by the 
enzymatic activity of a metallo-protease named ADAMTS-1348-50 (Figure 3). 
A deficiency in the ADAMTS-13 protease activity results in the presence of 
ultra-large VWF multimers that may cause thrombotic thrombocytopenic 
purpura51 (TTP), which is manifested by thrombocytopenia, 
microangiophatic hemolytic anemia, bleedings and other symptoms52. 
Several VWF domain-specific functions have been identified and 
elucidated. D domain contains FVIII and heparin binding site and, in 
addition, D’D3 may contain P-selectin site of interaction. P-selectin appears 
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to anchor released ultra-large multimers to the surface of activated 
endothelial cells and contribute to present ADAMTS-13 cleavage site53-55. 
A1 domain contains the binding site for platelet receptor GPIbα, heparin, 
sulphated glycolipids and snake venom botrocetin. It’s still controversial if 
this domain contain also a binding site for collagen56. Scientific researchers 
agree that collagens type I and III binding site are located within the A3 
domain. Integrin αIIβ3 binds to RGD sequence located within C1 domain. 
The A2 domain contains the ADAMTS-13 cleavage site. Both the A1 and A3 
binding sites and their accessibility seem to be dependent on the fluid 
dynamic forces exerted on the molecule as well as its immobilization on a 
surface40. 
The majority of binding sites for numerous ligand are located within A 
domains, in accordance to the evolutive properties of this kind of modules, 
characteristic of adhesive proteins57. On the other hand, amino and 
carboxy-terminal ends are more implicated in the VWF structure 
determination than in ligand binding.
Neither VWF structure nor its adhesive properties are dispensable to allow 
all VWF-dependent function at sites of vascular injury. This notion is 
supported by severe VWD due to mutations in either A and D-C domains. 
Introduction
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VON WILLEBRAND DISEASE
Von Willebrand Disease is an inherited bleeding disorder due to deficiency 
and or disfunction in von Willebrand factor protein, and is a relatively 
common cause of bleeding although the precise prevalence is very difficult 
to estimate ranging between very different values (0.0023%-1,3%)58. 
Considering only VWD due to genetic mutations occurring in the VWF 
genes, there is no evidence for a single major gene rearrangement 
associated to a large fraction or more severe cases58. Since the 192659, 
when a new  bleeding disorder different from haemophilia was described, 
and from the 1950s when the plasma factor was first named von Willebrand 
factor, up to 300 (http://www.ragtimedesign.com/vwf/mutation/) different 
mutations were founded throughout the 178 kb of DNA of the VWF gene. 
It is not known if the extremely heterogeneity observed for VWD is based 
on the features of  VWF as multifunctional protein, or on its complex 
biosynthesis with extensive post-translational processing and distinct 
pathways of intracellular transport and secretion. Faults could occur at any 
of this levels and could be associated with specific VWD types60.
VWD was classified in three major categories61: type 1 is the most frequent 
(70-80 % of  the cases), groups partial quantitative deficiencies (1-40% of 
normal VWF levels) and leads to highly variable phenotypes62-64, type 2 
collect all qualitative deficiencies and type 3, the most rare (approximately 
1/1 million), give rise to total deficiencies65-67.
Mutations related to decreased synthesis, impaired secretion, increased 
clearance or a combination of these conditions lead to low  VWF plasma 
levels in type 1 patients. Several studies showed that in more severe VWD 
type 1 cases, genetic changes are common within the VWF gene and 
highly penetrant. Genetic determinants in milder VWD type 1 cases involve 
factors in- and outside the VWF gene68,69.
Mutations causing type 2 VWD are often within VWF gene and interfere 
with protein structure or function64. Type 2 is divided into 4 subclasses: type 
2A, 2B, 2M and 2N. 
2A is the most common qualitative abnormality of  VWF and is associated 
with selective loss of large and intermediate-sized VWF multimers 
paralleled with decreased platelet-dependent function. The reduction of 
larger multimers is caused by either increased sensitivity to proteolysis by 
ADAMTS-13 or impaired multimer assembly within the Golgi70,71. 
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2B is also characterized by loss of larger multimers. However, in VWD type 
2B this is due to increased affinity of  mutated VWF for the platelet GPIb-IX-
V complex72. Gain-of-function mutations in the VWF-A1 domain lead to 
VWF with an abnormal conformation, which 'spontaneously' reacts with 
circulating platelets73,74.
2M includes variants in which platelet adhesion is impaired, due to 
abrogated binding to GPIbα (i.e. the opposite of  the VWD type 2B 
mutation). However, the VWF multimer distribution in these patients is 
normal75. 
Mutations in the VWF gene responsible for VWD type 2N cause defective 
binding to FVIII76,77. In these patients FVIII is not stabilized by VWF and 
clinical symptoms are similar of those of Haemophilia A78.
Figure 7: Schematic representation of expected lavoratory values in VWD 
types (Montgomery RR http://www.nhlbi.nih.gov/guidelines/vwd/
3_diagnosisandevaluation.htm)
In spite of great efforts to precisely describe and define single groups of 
mutations, many variations are controversially designated in different 
subtypes (Multiple patophysiologic mechanism) for example the C1149R 
change61 and the “Vicenza” mutation58 due to the complexity of the 
phenotype, and to discrepant interpretation of laboratory testing displaying 
an ample variation58,61.  
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VWD TYPE 2A and subtypes IIC, IID and IIE/F
VWD 2A includes all patients displaying lack or decreased HMWMs 
paralleled with decreased platelet-dependent funtion. However the 
molecular mechanism resulting in the loss of HMWMs and the mode of 
inheritance could be different61.
VWD due to defective assembly of VWF structure can be produced by 
mutations in the propeptide, C-terminal “Cysteine Knot” or D3 regions.
In recessive type IIC VWD, homozygous or coumpound heterozygous 
mutations in the VWF propeptide preventing multimerization in the Golgi 
apparatus are associated with characteristic simple multimer pattern that is 
essentially devoid of satellite bands and pronounced first band. The 
propeptide has an essential role in promoting multimer formation, possibly 
by catalyzing disulfide interchanges resulting in the interdimeric disulfide 
bonds60,61,79. The presence of  CGLC sequnce both in the D’ and D2 
domains (159-162 and 521-524 positions), which are homologous to the 
sequence of the catalytic site -CGXC- of the ER disulfide isomerase, 
support this notion. Mutations introduced at these positions result in 
unfeasible multimerization of recombinant VWF79. 
In type IID VWD, a multimer assembly defect is associated with 
heterozygous mutations in the CK domain preventing dimerization in the 
ER. As a result both proVWFmonomers and wild type dimers arrive in the 
Golgi where the binding of a mutated monomer to a normal dimer 
terminates the polymerization process at that extremity. The multimer 
pattern shows, in addition to normal multimer bands, less intense and odd 
intervening sub-bands located between normal oligomers containing small 
multimers made by normal dimers and mutated monomers60,61,79. 
In type IIE/F VWD, the cause of the multimerization inefficiency, have to be 
found in heterozygous mutations located within the D3 domain, often 
affecting Cys residues and interfering with inter-subunit disulfide bond 
formation in the Golgi during dimers association to form multimers. The 
resultant multimer pattern is often “smeary” that suggests an 
heterogeneous disulfide bond structure. Some other mutations in the D3 
domain are not associated to aberrant disulfide bond formation and result in 
different phenotype (i.e. type 2M “Vicenza VWD)60,61,79. 
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Figure 8: Multimer analysis of VWF from the plasma of patients with 
different VWD types compared with normal control reported by 
Schneppenheim R et al. 60 (gel concentration 1.5%). Plt = platelets’s VWF, 
displaying the characteristic presence of `supranormal' multimers and the 
lack of a triplet structure. Normal multimer pattern (N) displays a typical 
triplet structure and the high molecular weight multimers appear 
pronounced. Type IIC is associated to the lack of HMWMs and absence of 
a triplet structure of individual multimers. LMWMs and especially the first 
band, are markedly pronounced. Intervening bands as in VWD IID, 
representing multimers with an odd number of monomers, are absent. The 
similarity between types IID and IIC is based on the absence of a triplet 
structure, the lack of high molecular weight multimers, and the pronounced 
bands of smaller multimers, albeit not as marked as in type IIC. The 
intervening bands result from the dimerization defect. The type IIE/F 
multimer pattern is characterized by a lack or relative decrease of HMWMs 
and the absence of the outer sub-bands of the normal triplet structure. 
Inner sub-bands, closer to the central band, are present, which give the 
individual multimer a broader appearance60.
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RNA-INTERFERENCE: CORRECTION APPROACH TO DOMINANT 
DISEASES
RNA interference (RNAi) is a recently discovered mechanism in which gene 
expression is regulated by small double-stranded RNA (dsRNA) molecules 
that inhibit gene expression with complemetary nucleotide sequences80. 
The RNAi machinery acts by either suppressing transcription 
(transcriptional gene silencing) or activating a sequence-specific RNA 
degradation process (post-transciptional gene silencing)81.
Essentially RNAi (Figure 9) is divided in two major steps. First, in the 
“RNAi-initiating step” large dsRNA are bound by RNA nuclases and cleaved 
in discrete 21- to 25-nucleotide RNA fragments called small dsRNAs. In the 
second step, these short dsRNA molecules (called miRNAs if  derived from 
endogenously cleaved long dsRNA, or siRNAs if exogenously synthesized 
and introduced inside cells) are associated in the cytoplasm with a protein 
complex defined as RISC (RNA-induced silencing complex), one of the two 
RNA strand is degraded and the remaining guide strand mediates the 
sequence-specific degradation of the corresponding mRNA (in the case of 
siRNAs) and/or translational repression by binding to the 3’ untraslated 
region (UTR) in the case of miRNAs80-82.
The existence of the RNAi machinery, that mediate gene expression 
regulation and/or, in some cases, protection from dangerous (i.e. viral) 
external RNAs, also give the opportunity to take advantage on this 
endogenous process to induce the silencing of  virtually any gene of 
interest80.
For this reason RNAi-mediated silencing is recently become an extremely 
used and useful tool in the reverse genetic analysis of gene functions and it 
also represents a potential novel drugs for the treatment of diseases80.
Due to the apparent simplicity of  the mechanism, which offer almost 
unlimited silencing applications based only on the sequence availability of 
the mRNA you want to silence, a large and increasing number of studies 
have reported fascinating application of  the RNAi strategy to numerous 
disease for which effective treatment are currently unavailable or sub-
potential, i.e. viral infection, cancer, autoimmune-  neurodegenerative- and 
cardiovascular-diseases,... although some important and not omissible 
limitations have not yet been resolved80. 
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Figure 9: Simple schematic representation of the RNAi mechanism 
focusing on the exogenous siRNAs silencing action.
The major impediment for the clinical use of  siRNAs is their poor cellular 
uptake and short serum half-life. Although great progress has been made 
on this regard, researches are currently open to find the most selectively, 
safe and potent delivery system for siRNAs.
In spite of this, numerous preclinical studies allowed the establishment of 
some clinical trials: phase I-II for age-related macular degeneration (AMD) 
and respiratory syncytial virus (RSV)80. 
The primary aim of human gene therapy is to correct the genetic disorder 
caused by mutation specific effects. Basically recessive disorders are 
approached with replacement therapy that, introducing wild type allele, 
restores gene function and improves disease pathology. On the other hand 
dominant phenotypes may be caused by haploinsufficiency (reduction of 
the wild type protein level), by gain of function mutation or both. The 
suppression of the detrimental effects of  the mutated allele together with 
the maintenance of  the wild type allele expression are necessary to 
overcome the effects of  a gain of function mutation. These features make 
dominant inherited diseases perfect candidates for RNAi-based gene 
therapy83.
Several dominant disorders have already been approached, in vitro or in 
animal models, with RNAi such as Huntington’s disease (HD), 
spinocerebellar ataxia type 1 (SCA1), amyotrophic lateral sclerosis (ALS), 
Introduction
17
Alzheimer’s disease, myotonic dystrophy (DMI) all caused by triplet 
expansion.
When dominant mutations occur within gene coding for protein which 
needs to aggregate to function properly, a dominant-negative effect is 
expected. In this case a severe phenotype is often observed, because wild 
type and mutant proteins interact and also the wild type molecule is not 
available to carry out its function.
Mutations with dominant-negative effect are classically detectable in 
structural proteins i.e. collagen or nonstructural proteins that dimerize or 
oligomerize i.e. transcription factors of  the b-HLH-Zip family, which bind the 
DNA as dimers, or ion channels located in cell membranes, which are often 
multi-protein complex84.
Recently are reported that RNAi-mediated gene silencing could be a 
promising treatment for the pachyonychia congenita85,86 (PC), which 
represent one of the numerous skin disorder associated to one of  the 54 
human keratin genes, and is associated to dominant-negative mutations. 
PC represent a suitable disease to test RNAi treatment because offer some 
advantages such as the presence of recurrent mutations, and the external 
location and focal nature of the plantar skin lesions permitting minimally 
invasive localized treatments to be performed on patients. The discover of 
potent and selective siRNA tergeting the most common mutation causing 
PC resulted in the initiation in 2008 of a clinical trial for this skin disorder.
VWF displays extraordinary adhesive features: it polymerizes with itself  and 
exploits its function through the binding with collagen, platelet receptors 
and other ligands. For these reasons it is expected that mutations in the 
related VWF gene could have dominant-negative effect. Furthermore VWF 
is synthesized in endothelial cells and megacaryocyte only, suggesting that, 
in the future, the treatment could be localized to these cell types.
Finally VWD is the most prevalent hemostatic disorder and the majority of 
its cases are dominantly inherited and could be potentially approached with 
RNAi treatment.  
However, on the contrary to PC, over 300 mutations are associated to VWD 
and none of these is demonstrated to be the most prevalent. This would 
imply that very specific siRNAs have to be designed and tested for each 
VWD-associated mutations that you want to correct.
VWF is also a large protein that undergoes numerous and regulated post-
trancriptional modifications and the setting studies to found effective 
siRNAs molecules need to be careful and rigorous.
Introduction
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For the sake of clarity some important advises for RNAi study design are 
reported below81,83. 
The use of  siRNAs to silence gene expression in mammalian cells involves 
a careful consideration of selecting the siRNA sequences in the target gene 
to avoid non specific complementariry to unrelated genes and to avoid the 
choice of  target site not accessible for the binding of the siRNA. It may be 
necessary to screen several sequences, concentrations, combinations and 
delivery systems to identify the most efficacy molecule for each cellular 
model. Today are available helpful on-line software, that provided RNA 
structure models to give information on the site accessibility or offering 
automated researches for siRNAs sequences with more probability to be 
effective that can help in the choice of siRNAs molecules. In addition it is 
essential to accurately optimize the transfection protocol depending on: the 
target cell type, the selected means such as siRNas or vector-driven 
shRNAs and the delivery system. 
Introduction
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BACKGROUND INFORMATION OF THE 
p.P1105_C1926delinsR GENE DELETION AND OUTLINE 
OF THIS THESIS
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We have previously described a large, de novo and heterozygous deletion 
in VWF gene associated to a variant type 2 VWD. The propositus showed a 
severe VWF deficiency, as indicated by reduced ristocetin cofactor activity 
(3%) and prolonged bleeding time (20 minutes), which produced a number 
of bleeding symptoms requiring blood transfusion [Bernardi 1990 Blood]. 
The altered multimer pattern (Figure 10) was characterized by reduced 
intermediate- and no HMWMs in plasma and platelets, and by abnormal 
morphology of  triplets with a broad band apparently containing a fast-
migrating component. Antigen (VWF:Ag) levels (24%) and FVIII coagulant 
activity (29%) were also reduced87. The gene deletion boundaries were 
mapped within introns 25 and 3488 and the new  junction between exons 25 
and 35 was sequenced after reverse transcription of the platelet RNA 
(Figure 11). At the protein level Cysteine 1104 should be connected in-
frame with mutated codon 1926 (cysteine to arginine). 
The encoded protein (Figure 12) would lack the last part of the D3 domain, 
the A1, A2 and A3 modules, and the first part of the D4 domain, which 
would virtually abolish, in addition to the A domain-associated adhesive 
function89-92, the D3 domain-associated inter-dimer disulfide bond 
formation93,94 and thus multimerization. However, the dominant-negative 
attitude of  the deleted protein still needs to be demonstrated, and its 
molecular features dissected.  Dimerization and multimerization, distinct 
property of  VWF producing extremely large and adhesive molecules, 
provide the rationale for the dominant inheritance caused by the interaction 
of wild type and mutant VWF monomers during polymerization. The 
strength of  the negative effects produced by dominant variants would be 
associated with the ample variation of  residual VWF level and function, and 
would participate in the phenotypic penetrance and severity of VWD types 
inherited as dominant traits, which is rather high95. These are major open 
questions in VWF biology and VWD molecular bases definition.
In this study we constructed a cellular model of  this unique disease variant 
as a tool to demonstrate the presence, and evaluate the efficiency, of  the 
dominant-negative effect of the deleted protein in the biosynthetic steps of 
VWF maturation and secretion. This cellular model mimics patient’s plasma 
VWF phenotype and highlights the key role of heterodimer between normal 
and deleted VWF molecules. We also propose a silencing approach to 
correct the dominant-negative effect that partially restored VWF levels.
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Figure 10: Multimer analysis of plasma (A) and platelet (B) and 
densitometric scans (C) reported by Bernardi F et al.87
N: normal control; F and M. father and mother of the propositus (P). In lane 
b a double amount of plasma of the propositus was loaded and in lane c an 
antiproteolytic mixture was added as anticoagulant. (C) Densitometric 
analysis of lanes reported in (B).
N P F M B
bleeding time (min) 5-8 20 5 7 8
FVIII:C 60-170 29 98 70 75
VWF:Ag 60-150 24 98 102 72
Ri:Cof 60-150 3 93 76 70
Table 187: Hemostatic parameters in members of the propositus’s family as 
in Bernardi et al. 1990 Blood. N = normal range, P = propositus, F = father,  
M = mother, B = brother.
Background Information of the p.P1105_C1926delinsR
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Figure 11: Schematic representation of the deletion location within VWF 
gene and the resultant deleted mRNA. The box indicates the new junction 
that connected in-frame exons 25 and 35 thus mutating Cys 1926 to Arg.
Figure 12: Schematic representation of the wild type and deleted VWF 
protein domains. Dark-grey motifs (1105-1925 amino acids) are missed in 
the deleted VWF.
Background Information of the p.P1105_C1926delinsR
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MATERIAL & METHODS
24
Creation of expression vectors
The expression vector pSVHVWF1 for human VWF, having the full-length 
VWF cDNA cloned into the pSV7d plasmid, was a generous gift from Prof. 
J.E. Sadler (Washington University in St. Louis)25.
Figure 13: Schematic representation of wild type, deleted and double 
mutated VWF-expression vectors. Black arrow within pDEL and pDEL/
C2773R indicates the breakpoint. Black bordered flags indicate siRNAs 
complementary regions. Squared brackets indicate epitopes recognized by 
antibodies utilized in Western blotting experiments.
To create the pSVHVWF-P1105_C1926delinsR96,97 (Figure 13) deleted 
expression vector (defined as pDEL) the SacI restriction site at position 
8876 was initially abolished by site-directed mutagenesis through the 
mutagenic primers 5’CCACAATAAAGGCTCAGCTCTTATCTTGC3’ (change 
underlined) and 5‘GCAAGATAAGAGCTGAGCCTTTATTGTGG3’ by using 
the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
CA). The transient expression of the pSVHVWF variant in monkey kidney 
cells (COS-1) resulted in secreted VWF antigen and VWF collagen-binding 
activity levels indistinguishable from that of  the pSVHVWF1, and 
pSVHVWF was subsequently used as wild type VWF expression vector 
(pWT).  
To reproduce the P1105_C1926delinsR deletion we exploited the 
overlapping PCR strategy98,99 (Figure 14) with appropriately designed 
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primers. Primers 5’CAATGACCTCACCAGCAGCAACC3’ (VWF-25F) and 
5’TGCCTGTGCACACGCGGCACAATGTGGCCGTCCTCC3’ (VWF-25R), 
having a 15 bp-tail complementary to nt 6153-6167 in exon 35, were used 
to ampl i fy the region upstream of the breakpoint. Pr imers 
5’CGGCCACATTGTGCCGCGTGTGCACAGGCAGCTCC3’ (VWF-35F), 
having a 15 bp-tail complementary to nt 3675-3689 in exon 25, and 
5’TCTTCAGGGACACAGCTGCC3’ (VWF-35R) were used to amplify the 
region downstream of the breakpoint. The partially overlapping regions 
were amplified using the pWT as template (30 cycles; 30’’ at 94°C, 30’’ at 
55°C, 50’’ at 72°C). Amplicons were then purified and mixed for a third PCR 
reaction using the VWF-25F and VWF-35R external primers. (30 cycles; 
30’’ at 94°C, 30’’ at 50°C, 1’ at 72°C). The resulting 1279 bp fragment was 
then cloned into the pWT vector utilizing SacI restriction sites at positions 
3395 and 6986.
Figure 14: Schematic representation of the overlapping strategy applied to 
produce the deleted vector.
 
To create the pDEL/C2773R (Figure 13) vector the C2773R mutation was 
inserted into the pDEL vector by site-directed mutagenesis using primers 
5 ’ G A G A C G C T C C A G G A C G G C T G T G A T A C T C 3 ’ a n d 
5’GAGTATCACAGCCGTCCTGGAGCGTCTC3’. 
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The correct sequence of vectors, and the absence of  undesired changes, 
was confirmed by direct sequencing.
Expression of recombinant VWF in eukaryotic cells
COS-1 cells were used for transient expression of VWF variants25. Cells 
were grown in Dulbecco modified Eagle’s medium (D-MEM) supplemented 
with 2 mM L-glutamine, 50 IU/ml penicillin, 50 µg/ml streptomycin, and 10% 
(vol/vol) fetal bovine serum and seeded at 60-70% confluence into 6-well 
plate for transfection. Single plasmids, or combination of them in the 
relative molar proportion reported in the figures were transfected into 
COS-1 cells by using Lipofectamine2000 (Invitrogen, Carlsbad, CA) and in 
the presence of Opti-MEM serum-free medium (Invitrogen). The total 
amount of  DNA in each transfection was set to 4.5 µg by adding, when 
needed, a gutted pUC18 plasmid. Seventy-two hours after transfection the 
conditioned media were collected and cells were lysed for total RNA 
isolation (NucleoSpin RNAII isolation Kit, Macherey-Nagel GmbH&Co. KG, 
Duren, Germany) or intracellular VWF investigations (lysis buffer: NaCl 150 
mM, Triton X-100 1%, Tris HCl pH 7.4 50 mM, PMSF 1 mM, Benzamidine 
10 mM).
Silencing
The siRNA 852 (sense, 5’CCUCGGACCCUUAUGACUUUU3’; antisense 
5’AAGUCAUAAGGGUCCGAGGUU3’), to specifically silence the wild type 
V W F e x p r e s s i o n , a n d t h e s i N C ( s e n s e , 
5 ’ C C U C A G U C C U A U A G C G C U U U U 3 ’ ; a n t i s e n s e 
5’AAGCGCUAUAGGACUGAGGUU3’), as negative control, were designed 
by the Invitrogen software BLOCK-iT™ RNAi Designer (https://
rnaidesigner.classic.invitrogen.com) and purchased (Figures 13-14).
Conversely, none of  the on-line available software programs for the siRNA 
design were able to predict a siRNAs targeting the naturally occurring 
breakpoint region of  the mutated VWF variant, and hence able to 
selectively inhibit the pDEL expression.
To overcome this limitation we first evaluated the VWF mRNA conformation 
at the breakpoint region and its theoretical accessibility to complementary 
siRNA with the Mfold100 software (http://mfold.bioinfo.rpi.edu/).
Material and Methods
27
Figure 15: Example of RNA fold made by the mfold on-line software. The 
figure showed a small part of the entire RNA structure of the deleted 
molecule surrounding the breakpoint (bold line). In this simplified image the 
availability of the site is evident.
The si3681 (sense 5’CAUUGUGCCGCGUGUGCACUU3’; antisense 
5’GUGCACACGCGGCACAAUG UU3’) and the si3675 (sense, 
5’CGGCCACAUUGUGCCGCGUUU3’; antisense, 5’ACGCGGCACA 
AUGUGGCCGUU3’) oligoribonucleotides complementary to the breakpoint 
region were then designed (Figure 16-17) in the respect of  the siRNA 
design rules and purchased from Invitrogen. 
siRNAs (10-80 nM) were transfected, with VWF expression vectors in 
COS-1 cells by Lipofectamine2000 (Invitrogen). Medium was replaced with 
fresh Opti-MEM 4 hours after transfection. Conditioned media and cells 
were collected as above mentioned.
Preliminary studies were conducted to achive the most efficacy silencing 
activity of the si3675 and si3681 and their combination toward the pDEL 
expression, and the appropriate experimental conditions to avoid adverse 
effects. Treatment with 40 nM of si3681, complementary to the breakpoint 
sequence exactly in the middle of  its sequence, was chosen as the most 
efficient.
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Figure 16. Deleted VWF sequence fragment and siRNAs.
Position and sequence of the mRNA and of the siRNAs (flags) directed to 
the mRNA breakpoint (3’ of exon 25 and 5’ of exon 35). Nucleotides at the 
junction (arrow) are indicated by bigger/bold letters.
Figure 17: Schematic representation of siRNAs targeting region (across the 
breakpoint) within pDEL.
mRNA study
Reverse-transcription (RT) was performed using “SuperScript III First-
Strand Synthesis System” (Invitrogen) and oligo (dT). PCR amplification 
(30 cycles; 30’’ at 94°C, 30’’ at 50°C, 30’’ at 72°C) was performed with 
forward primer 5’CAGTGACGTCTTCCAGGAC3’ and reverse primers 
5’AGGGTCACTGGGATTCAAGG3’ and 5’TGCCTGTGCACACGCGGC3’ 
designed on pWT and pDEL vectors, respectively. Capillary electrophoresis 
was performed on the Experion automated electrophoresis station101 (Bio-
Rad Laboratories, Hercules CA, USA) to detect amplification products. This 
method applies a combination of microfluidic separation technology and 
sensitive fluorescent sample detection to perform, in our cases, RNA 
automated analysis. All gel-based electrophoretic steps are automatically 
performed to generate reproducible separation and quantitative results, 
which may be reported as an electropherogram gel image (Figure 31A) or 
scheduled.
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Antibodies
Polyclonal Rabbit anti-human VWF (A0082), polyclonal rabbit anti-human 
VWF/HRP (P0226), polyclonal swine anti-rabbit immunoglobulins/TRITC 
(R0156) and polyclonal Goat Anti-Mouse IgG/HRP antibodies were 
purchased from DAKO (DAKO, Glostrup, Denmark). The mouse 
monoclonal [2G11] antibody to Mannose 6-Phosphate Receptor (late 
endosomes marker) (ab2733) and the mouse monoclonal [1D3] to PDI (ER 
marker) (ab12225) were purchased from Abcam (Cambridge, UK). The 
FITC-conjugated AffiniPure goat anti-mouse IgG (H+L) (115-095-146) was 
from Jackson ImmunoResearch Laboratories (Baltimore, USA). Monoclonal 
anti-VWF M31 and M13 were obtained as described102,103. 
Analysis of recombinant VWF
VWF:Ag in conditioned media and cell lysates was determined by an 
ELISA assay performed with above mentioned Dako antibodies (Polyclonal 
Rabbit anti-human VWF and polyclonal rabbit anti-human VWF/HRP).  The 
ELISA assay described by Federici et al.104 was tested and partially 
modified to obtain better results. Essentially the blocking solution is based 
on PBS instead of  TBS because, although both showed good response to 
scalar dilutions of  a pool of normal plasma, the first one showed lower 
values of  background. In order to increase the relative absorbance of  each 
samples several primary antibody concentrations are tested but all of  these 
gave similar good results. When different concentrations of  secondary 
antibody are used a good improvement in the absorbance values was 
obtained doubling (1 µg/ml) the proposed concentration (0.5 µg/ml). Intra-
assay coefficient of variation was ≃ 6.5% and the inter-assay was ≃ 15%. 
Sensitivity was ≃ 2 ng/ml.
VWF:CB was measured in conditioned media using the “CollagenBinding 
Assay kit” (Life therapeutics, Clarkston, USA).  
Multimer analysis: the multimeric structure of VWF was detected in sodium 
dodecyl sulfate (0.1%) agarose gel (1.5-3%) electrophoresis105,106 followed 
by Western blotting and detection with immunoenzymatic stain (polyclonal 
Goat Anti-Mouse IgG/HRP antibodies, Dako) or with radioactive detection 
(125I-anti-vWF antibody103).
Material and Methods
30
Western blotting of VWF present in media and lysates were performed in 
polyacrylamide gel (NuPAGE4-12% Bis-Tris Gel, Invitrogen) in reducing 
condition. The electrophoresis was performed in MOPS 1x buffer 
(Invitrogen) for approximately 5 hours at 200 V, followed by transfer in TRIS 
(25 mM)-glycine (192 mM) buffer with methanol (10% v/v) and sodium 
dodecyl sulfate (0.7 mM) at 300 mA for 2 hours. The nitrocellulose 
membranes were reacted with different anti-VWF monoclonal antibodies 
followed by incubation with anti-mouse Immunoglobulins/HRP (Dako). 
Bands were visualized by autoradiography with Amersham Hyperfilm ECL 
(GE Healthcare Limited, Pollards Wood, UK) using “Super Signal West 
FEMTO Maximum Sensitivity Substrate” for media and “Pierce ECL 
Western Blotting Substrate” for lysates (Pierce, Rockford, USA).
Immunofluorescence microscopy
Cells for immunofluorescence labelling were cultured at sub-confluence in 
6- or 12-wells on a coverslip of 12 or 24 mm of diameter. Cells were 
transfected with Lipofectamine2000 lipid reagent (Invitrogen) using a 2:1 
ratio for Lipofectamin/vectors. 24 hours after transfection cells were fixed in 
methanol for 7 minutes at -20°C and saturated with 4% Bovine Serum 
Albumin (BSA)/PBS. Subsequent incubation with primary and appropriate 
secondary antibodies was performed for 1 hour at room temperature. 
Primary antibodies were diluted 1:100 in 4% BSA/PBS and secondary 
antibodies were diluted 1:50 in the same solution. 
Images were acquired with a Nikon fluorescence microscope Eclipse 50i 
(Nikon Instruments, Sesto F.no, Firenze, Italy) equipped with DS-5M digital 
camera and DS-L1 control unit. Objectives used were Nikon Plan 20x/0.5 
and 40x/0.75 and Nikon 100x/0.5-1.25 Oil Iris.
Confocal images were acquired as previously described107 with a Zeiss 
LSM 510 microscope equipped with a Fluar 40x/1.3 oil immersion objective 
(Carl Zeiss, Arese, Italy). Briefly, 488 and 543 nm excitation wavelengths 
were provided respectively by Agron/2 and HeNE laser sources at a 5% 
intensity. 
Superimposition of red and green fluorescence, not specifically due to co-
localization, was excluded by applying to the green channel a beam path 
admitting the acquisition of fluorescence comprised among 505 and 550 
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nm and to the red channel a light path excluding all fluorescence below  560 
nm. Pinhole values were ranging from 40 to 80 µm. Where required, image 
magnification was obtained digitally with the LSM examiner software (Carl 
Zeiss). 
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Creation of the recombinant deleted expression vector (pDEL)
 To create the de le ted express ion vector pSVHVWF-
P1105_C1926delinsR96,97 (pDEL), the overlapping PCR method was used.
First we identified a fragment of the pSVHVWF1 vector containing the 
region to be deleted and delimited by SacI restriction sites. Dowstream of 
the deletion, near the end of  the VWF cDNA in the pSVHVWF1 vector, a 
third Sac I recognition site was present thus complicating the subsequent 
cloning step. To overcome this limitation we abolished the last Sac I 
(position 8876) restriction site through site-directed mutagenesis and 
produced the pSVHVWF (pWT) expression vector. 
The transient expression of the pSVHVWF variant in COS-1 cells resulted 
in secreted VWF antigen and collagen-binding activity levels 
indistinguishable from that of  the pSVHVWF1, and pSVHVWF was 
subsequently used as wild type VWF expression vector (pWT) (Figure 18).
Figure 18: VWF:Ag (light grey) and VWF:CB (dark grey) levels in 
conditioned media form cells transiently trasfected with pSVHVWF or 
pSVHVWF1. Mean values of three replicate of pSVHVWF were used as 
100% (570.6 ng/ml for antigen value and 152.3% of normal standard as CB 
value) and the mean of three replicate (±SEM) was used to evaluate 
pSVHVWF1 levels. t test was applied to exclude significative differences.
The overlapping PCR98,99 was be performed on this mutagenized vector.
First two separate PCR reaction were performed with primers 25F-25R and 
35F-35R, the pWT vector was used as template (Material & Methods 
Figure 14 and Figure 19).
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Figure 19: Eletrophoretic separation of 
partially overlapping fragments amplified 
in the two separate PCR step performed 
with 25F-25R and 35F-35R set of 
primers. 
Figure 20: Electrophoretic separation of 
the 1279 bp fragment that connected 
residues 3689 and 6153 thus “containing 
the deletion. 
The amplicons obtained, which partially overlap (Material and Methods, 
Figure 14) were electrophoresed on agarose gels, excised, purified and 
used as template for the third PCR amplification reaction performed with 
external 25F and 35R primers (Figure 20).  
Figure 21: Electophoretic 
separation of pSVHVWF and 
pSVHVWF1 expression 
vectors digested with Sac I 
restriction enzime. The arrow 
indicate the fragment excised 
and purified for the 
subsequent ligation step.
1116bp 
M8 
1279bp 
25F-35R 
M8 25F-25R 35F-35R 
!800bp 
!400bp 
883bp 
404bp 
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The 1279 bp fragment carrying the desired junction between nucleotides 
3689 and 6153, contained two Sac I recognition sites at each extremity and 
was then digested with Sac I restriction enzyme. Accordingly, the pWT 
vector that contained two recognition site, at positions 3391 before the 
breakpoint, and at position 6892 downstream of the breakpoint, was 
digested with the Sac I enzyme to produce compatible ends with the above 
described fragment containing the desired junction (Figure 21).
Finally the ligation between the “7.8 Kb fragment” and the digested “1279 
bp” fragment was performed. 
The resulting pDEL expression vector, which would produce a protein 
containing the expected junction between exons 25 and 35, was used to 
transfect COS cells alone or in combination with pWT vector.
Expression of the in-frame deleted VWF
 In order to investigate the molecular mechanism through which the 
heterozygous deletion P1105_C1926delinsR produced the severe VWD 
phenotype we first studied the expression of the deleted VWF both in 
media and cell lysates in the absence of the wild type protein (Figure 22).
For this purpose two antibody pools102,103 were used in Western blot 
analysis. The M31 pool (Figure 22A, left panels) reacts with VWF residues 
2244-2456, downstream of  the breakpoint (Material and Methods, Figure 
13), and would recognize only domains with a normal reading frame. The 
M13 pool (Figure 22A, right panels) reacts with VWF residues 1394-1473, 
located within the deletion boundaries and thus only with the wild type 
VWF. The comparison of  blots supported that the pDEL vector efficiently 
drove the biosynthesis of  the in-frame deleted molecule. The deleted VWF 
appeared to be only partially secreted (Figure 23), and its electrophoretic 
migration was compatible with the protein size (≈  160 kDa) inferred from 
the extent of the deleted domains (821 amino acids).  
Whereas traces of  the altered pro-VWF were detectable in lysates, only the 
mature form of the deleted VWF was secreted. Pro-wild type VWF was 
abundant both in media and lysates, in accordance with published 
data25,29,30. Antigen and collagen-binding levels in media from cells 
expressing the pDEL vector (Figure 22B) were very low  and undetectable, 
respectively. The multimer analysis in high resolution gels (Figure 25 -page 
40) showed the presence of a broad band with increased mobility as 
compared to wild type, and did not reveal the presence of tetramers.
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Figure 22.  Expression of the deleted VWF.
(A) Western blot analysis of wild type and deleted VWF performed on 
conditioned media (upper panels) and cell lysates (lower panels) with 
monoclonal antibody pool M31 and M13102,103. The M13 antibodies, 
targeting VWF A1 domains (right panels), recognize only wild type VWF. 
The M31 antibodies (left panels), targeting the C-terminal domains, indicate 
the in-frame translation of the deleted VWF. Migration of the mature wild 
type (matureWT-VWF) and deleted (matureDEL-VWF) proteins, and of 
forms containing the propeptide (proWT-VWF and proDEL-VWF), are 
indicated. In cell lysates additional bands containing the pro-wild type VWF 
and the pro-deleted VWF are detectable. The asterisks indicate (*) over-
exposure or (**) under-exposure of gels. (B) VWF:Ag (upper panel) and 
VWF:CB (lower panel) levels in conditioned media of COS-1 cells. Results 
(ng/ml) of three independent experiments are reported as Mean ± SEM. 
The right y axis indicates the percentage of wild type (100% VWF:Ag, 570.6 
ng/ml; 100% VWF:CB, 152.3 of normal standard). Statistical significance (* 
P< 0.001) was evaluated by one-way ANOVA with Bonferroni post-test.  
n.d., not detectable.
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Figure 23: Intact Western blot containing the entire panels displayed in 
Figure 22, Figure 24 and Figure 31. The relative molar amounts of vectors 
and siRNA are indicated in the table. Antibodies are indicated as in figure 
22. Conditioned media (panel A) were tested by the monoclonal antibody 
pool M31. Cell lysates (panels B and C) were tested by monoclonal 
antibodies M31 and M13.
Dominant-negative effect of the VWF deletion – cellular model
To mimic the heterozygous condition in COS-1 cells, the pWT vector was 
co-expressed with increasing amounts of the pDEL, which progressively 
decreased the levels of wild type VWF (Figure 24). Equimolar amounts of 
both plasmids produced 20% (112.3 ± 4.1 ng/ml, Figure 24A, upper panel) 
of wild type antigen levels (570.6 ± 26.5 ng/ml), and 2% of  collagen-binding 
activity (Figure 24A, lower panel). Accordingly, the ratio between VWF:CB 
and the antigen values dropped to 1/10 of that calculated for the wild type. 
A double proportion of the deleted vector decreased the VWF:Ag levels to 
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12% (70.6 ± 4.5 ng/ml) of  wild type, and abolished the collagen-binding 
activity.
 The Western blotting, performed in reduced conditions (Figure 24B) 
and thus able to evaluate the proportion of the normal and deleted VWF 
molecules, indicated that in co-expression experiments the altered VWF 
prevailed. Taking into account the pro-peptide and mature forms, the 
densitometric analysis in media and lysates indicates that the ratios 
between the altered and normal VWF were 1.8 and 3.5, respectively. 
Moreover, the absolute amounts of the deleted protein appeared to be 
increased in media from cells expressing both vectors (Figure 23).
Figure 24. Dominant-negative effect of the in-frame deleted VWF variant.
(A) VWF:Ag (upper panel) and VWF:CB (lower panel) levels in conditioned 
media of COS-1 cells. The relative molar amount of pWT and pDEL vectors 
is reported in the table. The right y axis and statistical analysis as in Figure 
22. (B) Western blot experiments in conditioned media (upper panel) and 
cell lysates (lower panel) with antibody pool M31.
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(C) Multimer pattern detected with 
immunoenzymatic stain from media obtained 
as described in the table. The inset reports 
samples tested by 125I-labelled-anti-vWF 
antibody to better visualize the deleted VWF 
form. 
The multimer analysis (Figure 24C and 25) of VWF in media from co-
transfected cells indicated that the pDEL expression impaired secretion of 
oligomers, particularly the HMW forms, in a dose dependent manner. A 
detailed interpretation of the observed pattern is complicated by the similar 
extent of the deleted (821 amino acids) and propeptide region (741 amino 
acids), which causes co-migration of  dimers (D) and tetramers (T) with 
different subunit composition (i.e. homodimers DA and heterodimers Dc, 
Figure 26). In spite of this limitation, the presence of  heterodimers (Db) 
between the wild type and deleted proteins was clearly detectable. As a 
matter of  fact, co-expression of pWT and pDEL vectors produced the extra-
band Db, the migration of which is faster than that of wild type and slower 
than that of the deleted homodimers Da (Figure 25).
Results
40
Figure 25. High resolution multimer analysis of VWF in media.
Based on VWF:Ag level evaluation 1 ng of VWF was loaded in each lane 
(A and B). Due to the low protein concentration in media from pDEL 
expressing cells 0.25 ng were loaded in C, and accordingly the gel was 
over-exposed. PNP was diluted 1/200. The relative molar amounts of each 
vector and siRNA are reported in the table. Distinguishable dimers (D) and 
tetramers (T) are indicated together with sub-band composition (DA-C and 
Da-c; TA-E and Ta-d) in accordance with the schematic representation (Figure 
26). Faint bands are tentatively defined and indicated in Italics. 
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Figure 26:  Schematic representation of dimers and tetramers -in 
accordance to Schward et al 2000108 and Turecek et al 2002109- reports the 
combinations of wild type pro- and mature-VWF (subscript uppercase 
letters) and mature-deleted-VWF (subscript lowercase letters). Proteins 
with different subunit composition but similar molecular weight, and thus co-
migrating, are represented on the same line. For the sake of clarity the 
DEL/C2773R VWF monomer, which is not expected to form polymers, is 
reported at the bottom of the scheme.
The comparison between media from pWT and pWT+pDEL expressing 
cells in the tetramer region (T) enabled us to gain additional information 
about heterodimer polymerization. The fast-migrating and smeared band 
observed after expression of  both vectors supported the presence of a 
number of heterotetramers, which could stem from the combination among 
pro-wild type, mature wild type and mature deleted VWF.  
Immunofluorescence staining of intact cells was used to investigate the 
biosynthesis and intracellular localization of normal and deleted protein, 
and the dominant-negative effect of  the altered VWF. Transfected cells 
were stained with polyclonal anti-human VWF antibodies and monoclonal 
antibodies directed to specific markers of subcellular compartments. 
Antibodies recognizing the protein disulfide isomerase and the Mannose 6-
phosphate receptor were used to investigate endoplasmic reticulum and 
late endosomes110, respectively. In the first compartment, we did not detect 
differences in the fluorescence patterns between the wild type and in-frame 
deleted VWF expressing cells (Figure 27). 
Results
42
Figure 27: Intracellular distribution of recombinant VWF in the ER. Cells 
transfected with the vectors indicated above the images (A-F) were co-
immunostained for VWF (TRITC, red) and protein disulfide isomerase 
(FITC, green) as ER marker. Images were acquired with Nikon Eclipse 50i 
equipped with DS-5M digital camera, DS-L1 control unit and Nikon Plan 
20x/0.5, 40x/0.75 and Nikon 100x/0.5-1.25 Oil Iris objectives. Images were 
taken at room temperature on fixed cells mounting in glycerol/1,4 
diazabicyclo[2.2.2]octane/DAPI medium.
Differently, the analysis of late endosomes (Figure 28) revealed that the 
degree of overlapping between the VWF (red)- and Mannose 6-phosphate 
receptor (green)-specific fluorescence was i) high in cells expressing the 
pWT vector (panels A-B), ii) barely detectable in cells expressing the pDEL 
(C-D), and iii) intermediate in cells expressing both vectors (E-F). Although 
the deleted protein was inefficiently transported to the late endosome 
compartment, the strong red fluorescence in pDEL expressing cells (C-D) 
indicated that the protein was efficiently synthesized, in accordance with 
data obtained in the reticulum (Figure 27), with Western Blot analysis 
(Figures 23 and 24B) and with ELISA antigen assay on cell lysates (Figure 
29).
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Figure 28: Intracellular distribution of recombinant VWF in late endosome 
compartment. Cells transfected with the vectors indicated above the 
images (A-H) were co-immunostained for VWF (TRITC, red) and mannose 
6-phosphate receptor (FITC, green) as late endosome marker. Images 
were taken with Carl Zeiss LSM 510 equipped with a Fluar 40x/1.3 oil 
immersion objective at room temperature on fixed cells mounting in 
glycerol/1,4 diazabicyclo[2.2.2]octane/DAPI medium. The superimposition 
of red and green fluorescence not specifically due to co-localization was 
excluded as described in materials and methods. Images in the upper 
panels were digitally zoomed in twice the original size with the LSM 
examiner software (Carl Zeiss, Arese, Italy).
Immunofluorescence microscopy experiments did not suggest 
accumulation of  the deleted protein inside co-transfected cells, an 
observation confirmed by Western blots and VWF antigen levels of cell 
lysates.
VWF:Ag levels in cell lysates (Figure 29) of pWT and pWT+pDEL 
expressing cells were not significantly different in spite of a remarkable 
decrease of VWF:Ag levels in conditioned media due to the addition of the 
pDEL vector. These observation was also true comparing pWT and pDEL 
or pWT and pWT+2xpDEL expressing cells.
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Figure 29: VWF:Ag evaluation in conditioned media (grey bars) and in cell 
lysates (black bars). Results of five independent experiments are reported 
as Mean ± SEM. Statistical significance (°P< 0.01; *P< 0.001) was 
evaluated by one-way ANOVA with Bonferroni post-test.
Taken together these experiments demonstrated the ability of the in-frame 
deleted VWF to interact with wild type VWF in the biosynthetic process, 
thus producing quantitative and qualitative alteration of secreted VWF, and 
particularly the impairment of HMWM formation.
Interfering with dimerization of the  in-frame deleted protein by a 
natural mutation affecting VWF dimerization (C2773R) 
 A key step for the dominant-negative effect is the ability of  the in-
frame deleted protein to form heterodimers with the wild type VWF. To 
investigate the interaction between the deleted and wild type protein we 
exploited natural missense changes interfering with VWF dimerization (type 
2A IID VWD)111,112, and among those the C2773R23. Cysteine 2773 was 
also selected because molecular modelling and expression of  norrin have 
supported its key role in dimerization through intersubunit disulfide bond 
formation24. The insertion of this missense change in the double mutant 
vector pDEL/C2773R (Material and Methods, Figure 13) was aimed at 
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impairing dimerization of the deleted VWF, when co-expressed with the wild 
type protein.
  Figure 30: Dominant-negative effect of the double mutant pDEL/C2773R 
VWF variant. (A) VWF:Ag (upper panel) and VWF:CB (lower panel) levels 
in conditioned media. The relative molar amounts of pWT, pDEL and pDEL/
C2773R vectors are reported in the table. Statistical significance (* P< 
0.001; ■ P< 0.05) and analysis as in Figure 22. The right y axis indicates 
the percentage of wild type (100% VWF:Ag, 531.7 ng/ml; 100% VWF:CB, 
117.9 of normal standard) (B) Multimer pattern and densitometric profile 
(GS 700 Imaging Densitometer and Quantity One® software, Bio-Rad). 1.7 
ng of VWF was loaded in each lane.
Comparison of  media from cells co-transfected with pWT + pDEL or pWT 
+pDEL/C2773R (Figure 30A) indicated that the combination of the deletion 
and point mutation produced low  antigen levels (13.6 ± 2.7% of  wild type) 
and appreciable collagen-binding activity (4.9 ± 0.7% of wild type). On the 
other hand, multimer patterns obtained by loading equal amounts of  VWF 
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(Figure 30B) revealed that the relative amounts of HMWMs produced by 
the pWT +pDEL/C2773R co-trasfection appeared indistinguishable from 
that of wild type. These findings were further detailed by multimer analysis 
performed in high resolution gels (Figure 25B). Cells expressing the pWT + 
pDEL/C2773R vectors produced normal oligomers (DA-B-C and TA-B-C-D-E) 
and did not secrete detectable amounts of heterodimers or 
heterotetramers. Moreover, the wild type, mature homodimers (DA) were 
better represented in these cells than in those expressing the pWT vector 
only (Figure 25A, B). It appeared that, in co-transfected COS cells, the 
propeptide cleavage of  the normal protein was relatively improved in the 
presence of  the double mutant VWF, and of the consequent slowdown of 
the VWF biosynthetic process.
 Taken together co-expression experiments supported the notion that 
reducing the efficiency of heterodimer formation, mediated by the C2773R 
change in the in-frame deleted VWF molecules, relatively improves the 
ability of wild type VWF to produce HMWMs.
Interfering with dimerization of the in-frame deleted protein by RNA 
silencing - Correction strategy
We investigated whether siRNAs (Material and Methods, Figure 13), 
specifically directed to the VWF mRNA breakpoint in the pDEL, were able 
to rescue wild type VWF biosynthesis and secretion. 
To find the most selective and efficient silencing molecules we tested in 
preliminary experiments two siRNAs complementary to the breakpoint 
sequence. Evaluation at the VWF mRNA level by RT-PCR and denaturing 
capillary electrophoresis led us to select the si3681 molecule, which at 
40nM was able to substantially and selectively decrease the deleted VWF 
mRNA level (Figure 31A). 
The positive effects of the si3681 were detectable in the fluorescence 
pattern of treated cells, which appeared similar to that of wild type VWF 
expressing cells (Figure 28, panels G-H vs A-B).
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 Figure 31. Counteracting the dominant-negative effect by allele specific 
silencing. (A) Wild type and deleted mRNA before and after si3681 
treatment detected by capillary electrophoresis of RT PCR products. 
(B) Western blot analysis of conditioned media (upper panel) and cell 
lysates (lower panel) with M31 antibody pool.
Western blotting results (Figure 31B) demonstrated at the protein level that 
the silencing treatment substantially modified the proportion between 
secreted wild type and deleted molecules, favouring the wild type. This 
occurred both in the extracellular space (Figure 31B, upper panel) and in 
the intracellular compartments (Figure 31B, lower panel). The densitometric 
analysis indicates that the ratios between the altered and normal VWF 
decreased from 3.5 to 0.5 in lysates, and from 1.8 to 0.3 in media 
respectively. The si3681 treatment produced a three-fold increase in 
antigen levels (up to 74.8 ± 5.0 % of wild type, Figure 31C, upper panel). 
Moreover, the collagen-binding activity, undetectable before the treatment, 
improved to 28.0 ± 3.3% of wild type (Figure 31C, lower panel). As control 
the si3681 did not influence (VWF:Ag, 96.5%) wild type expression.
Results
48
Figure 31(C): VWF:Ag and VWF:CB levels and from conditioned media. 
The relative molar amount of pWT and pDEL vectors, and concentration of 
siRNAs are reported in the tables. Statistical significance (* P< 0.001; ° P< 
0.01) and analysis as in Figure 22. The right y axis indicates the 
percentage of wild type (100% VWF:Ag, 233.0 ng/ml; 100% VWF:CB, 53.8 
% of normal standard).
Moreover, a negative control siRNA (siNC) did not induce appreciable 
alterations of VWF levels in pWT+pDEL expression and a positive control 
(si852), appropriately designed to silence the expression of wild type VWF, 
produced a quantitative defect characterized by markedly reduced VWF:Ag 
and VWF:CB levels (P< 0.001). No changes in cell morphology or cell 
density were observed by bright-field microscopy after siRNA treatment (not 
shown). 
The si3681-mediated amelioration of antigen and collagen-binding activity 
in media of  co-transfected cells were reflected in the increase in amount of 
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HMWMs (Figure 31D). Moreover, the high resolution gels (Figure 25B) 
indicated that the bands containing wild type homodimers (DB-C) and 
homotetramers (TD-E) were increased in intensity.  
Taken together these data support both quantitative and qualitative 
improvement induced by the siRNA treatment.
Figure 31(D): Multimer analysis of condition media from transiently 
transfected cells. Left panel, equal volume of media; right panel, equal 
amount of VWF (1.7 ng). The relative molar amount of vectors and siRNAs 
were indicated in the table.
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The definition of  the molecular mechanisms leading to the dominant 
inheritance of  most VWD types is a key step to understanding the disease 
pathophysiology, which has a major role in determining its prevalence, and 
requires mutation-based cellular models. 
The cellular model of  the heterozygous and in-frame deletion under study 
represents a valuable tool to investigate the dominant-negative mechanism 
hypothesized6 to be responsible for a severe type 2 VWD form. The design 
and expression of recombinant vectors enabled us to evaluate through 
several methodological approaches the main biosynthetic steps of the 
deleted protein, and its interaction with wild type VWF. Improved knowledge 
of the detrimental properties of the altered protein led us to propose and 
explore strategies to counteract its effects. 
 Noticeably, conditioned media from cells expressing the deleted and 
wild type mRNA closely mirrored the severe defect observed in patient 
plasma. In spite of the limitation imposed by cell culture model, striking 
similarity was detectable for protein amounts (VWF:Ag, 19.7 ± 0.7% vs 24), 
quality (virtual absence of HMWMs) and thus function (VWF:CB, 2.9 ± 
0.7% vs VWF:RCo, 3%). These results were consistent with the presence 
of a particularly efficient dominant-negative mechanism, the molecular 
bases of  which were investigated in relation to deleted monomer 
expression, dimer and multimer formation, propeptide cleavage and 
subcellular localization of VWF. 
 In cells transfected with the deleted construct, the altered mRNA 
was efficiently translated, as indicated by the large amounts of the deleted 
VWF in cell lysates. Inside co-transfected cells, the deleted protein was 
much more represented than the wild type form, which would potentiate the 
dominant-negative effect of the altered molecules. In addition, the quantity 
of the deleted protein appeared to be higher in conditioned media of cells 
co-expressing wild type VWF than of  those transfected with the pDEL 
vector only.
 Formation of dimers between normal and deleted VWF 
(heterodimers), which should play a key role in the dominant-negative 
behaviour, would be sustained by the “cysteine knot” domain, a motif 
localised at the carboxyl-terminus of  the protein20,113 that was correctly 
encoded in the deleted VWF. As a matter of  fact, our analysis of 
conditioned media in high resolution gels indicated the presence of 
heterodimers and of deleted homodimers, thus implying both a properly 
folded domain and its ability to participate in the process. The absence of 
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all A domains does not limit dimerization, in accordance with the notion that 
these modules are not involved in the process, and with features and 
evolution of A domain-containing proteins57.
 On the other hand, formation of multimers containing the deleted 
protein should be impaired in the absence of the D3 sequence C1222-
C1227, containing the Cys residue responsible for the inter-dimer disulfide 
bond22,93,94. Whereas deleted homodimers cannot sustain any subsequent 
polymerization step (Figure 32), the heterodimer can ensure only an 
asymmetric multimerization giving rise to heterotetramers, which were 
detected in high resolution gels. According to their ability to form only one 
disulfide bond with pre-existing dimers or multimers, the heterodimer could 
act as terminator99,111 of  the multimerization process (Figure 32). The 
multimer pattern, and the abundance of the deleted VWF in Western blots 
of media from co-transfected cells, support the presence of remarkable 
amounts of terminated LMWMs, which do not contain unpaired bands due 
to the efficient dimerization of altered molecules. 
Figure 32: Schematic representation of the termination mechanism. The 
deleted monomer can dimerize through its normal C-terminal end but 
cannot multimerize through its N-terminal extremity. A dimer containing two 
deleted monomers cannot further polymerize. When an heterodimer is 
added to a growing polymer it stops the multimerization process at the 
selected extremity.
 
Impairment of  multimer formation by heterodimers is further sustained by 
expression experiments with a double mutant vector, containing both the 
deletion and the C2773R change, a well described mutation that prevents 
dimerization23,111. By co-expressing wild type and double mutant vectors we 
expected to decrease the dominant-negative effect of  the deletion, and to 
transform a qualitative VWD form in a quantitative defect, characterized by 
similarly reduced antigen and activity levels. Accordingly, the observed 
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mult imeric pattern showed a relat ive proport ion of HMWMs 
indistinguishable from normal. This feature, and the virtually exclusive 
presence of normal oligomers in high resolution gels, indicate that the 
C2773R mutation, preventing heterodimer formation, shifts the equilibrium 
towards wild type HMWMs. On the other hand the double mutant maintains 
a dominant negative character as indicated by the remarkable reduction in 
antigen levels.
 The multimerization and propeptide cleavage steps are catalysed by 
independent enzymatic activities29-32, the efficiency of which can be 
compared for the deleted and wild type VWF. Since pro-deleted VWF is 
barely detectable within cells and undetectable in media, dimers containing 
the deleted protein appear to be preferentially cleaved by furin-like 
endopeptidase activity29 as compared with wild type dimers. Although the 
genuine nature of  this observation cannot be established in COS cells, both 
structural features of  the deleted VWF, and increased residence time in 
endopeptidase-containing compartments, could favour protein cleavage. 
As a consequence, the poor attitude of  the deleted VWF to multimerize was 
coupled with complete propeptide proteolysis at the intracellular level. 
 Multimers are either secreted or stored in Weibel Palade bodies that 
cannot be investigated in COS cells25. However, the cellular model under 
study provides some information about the intracellular localization of  VWF, 
and potentially to accumulation of abnormal proteins, which would 
contribute to the decreased amount of secreted molecules. As determined 
by cell immunostaining, late endosomes of  cells expressing a single 
construct contained higher amounts of wild type than deleted VWF, in 
accordance with the low  amount of  altered protein in media. Coherently, co-
transfected cells displayed an intermediate amount of  VWF in this 
compartment. 
Neither in transfection nor in co-transfection experiments we obtained 
evidence for sites of intracellular accumulation. As comparison, the 
extensively studied dominant-negative C1149R mutation resulted in 
intracellular retention of mutant molecules114-116, suggesting that 
intracellular removal would be more efficient for the deleted than for the 
missense VWF variant.  
Overall data provide experimental evidence for a series of coherent 
features, which pertain to the molecular mechanism of the observed 
dominant-negative effects:
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i) the deleted protein is synthesized and folded in large 
amounts, and is preferentially processed 
ii) the deleted protein exhibits a correct C-terminal end and 
thus eff iciently forms altered homodimers and 
heterodimers with wild type VWF (Figure 32), the last 
prevailing in media of co-transfected cells
iii)  the heterodimers would be modestly affected by the quality 
control in the endoplasmic reticulum, which would favour 
their role as terminator molecules99,111 of the 
multimerization process (Figure 32) in the Golgi 
compartment 
iv)  reduced amounts of  VWF are detectable in the late 
endosome compartment and secreted as LMWMs.
 To further investigate the dominant-negative molecular mechanism 
of the deletion, and to suppress its effects, we successfully used a silencing 
approach117,118, selectively targeting the deleted RNA. This is an original 
attempt aimed at correcting VWD phenotype, albeit at the cellular level. 
 Although targeting of the siRNAs was limited by the short and obliged 
sequence of the breakpoint region, where exon 25 and 35 are joined, we 
devised an efficient molecule that significantly decreased the amount of  the 
deleted VWF mRNA. Since reduced amount of  the deleted mRNA persisted 
after RNAi treatment, VWF function was largely improved but not 
completely restored. 
By removing the effects of the deleted construct, the results of  the RNA 
interference formally validate the presence of  the dominant-negative 
mechanism: the reduced availability of the deleted mRNA and protein 
decreased the rate of heterodimer formation. As a consequence the 
treatment resulted in i) increased availability of mature wild type VWF, ii) 
appearance of HMWMs in media of  treated cells and iii) increase of the 
collagen-binding activity.  
 Although these novel findings have to be confirmed in patient’s cells, 
they pave the way to an in vivo application aimed at curing119 the unique 
patient under study and, because dominant-negative mechanisms are 
shared with others diseases, at devising correction strategies for other 
genetic conditions.
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ABSTRACT:
Understanding molecular mechanisms leading to the dominant inheritance 
of von Willebrand disease (VWD) would improve our knowledge on 
pathophysiological aspects underlying its high prevalence. We produced a 
cellular model of  severe type 2 VWD, caused by an heterozygous deletion 
in the VWF gene, to investigate the altered biosynthesis. Co-expression of 
the VWF in-frame deleted cDNA (p.P1105_C1926delinsR) impaired wild 
type vector-driven protein secretion and function (VWF collagen-binding 1.9 
± 0,5% of wt), which mimicked the patient’s phenotype.  
Protein studies and cell immunostaining delineated the highly efficient 
dominant-negative mechanism. The deleted VWF was synthesized in large 
amounts and preferentially processed, and through a correctly encoded 
“cysteine knot” domain formed heterodimers and heterotetramers with wild 
type VWF. Impaired multimerization was associated with reduced amounts 
of VWF in late endosomes. 
The key role of heterodimers as multimer terminators was further supported 
by introduction of the dimerization mutation C2773R in the deleted 
construct, which resulted in a quantitative defect with normal multimer size. 
Targeting the mRNA breakpoint by siRNA selectively inhibited the in-frame 
deleted VWF expression, and restored secretion of functional VWF (28.0 ± 
3.3% of wt). This provided a novel tool to explore mutation-specific gene 
therapy in a severe form of dominant VWD.
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RIASSUNTO IN ITALIANO:
La comprensione dei meccanismi molecolari che determinano l’ereditarietà 
di tipo dominante della malattia di von Willebrand aumenta, di 
conseguenza, la conoscenza degli aspetti patofisiologici che determinano 
la sua prevalenza. Abbiamo prodotto un modello cellulare di un severo 
caso di malattia di von Willebrand tipo 2, causato da una delezione 
presente in eterozigosi nel gene del fattore di von Willebrand (VWF), per 
studiare la biosintesi della proteina mutata. La co-espressione del cDNA 
contenente la delezione “in-frame” (p.P1105_C1926delinsR) diminuisce la 
secrezione e la funzionalità della proteina derivante dall’espressione del 
vettore “wild type” (VWF:CB 1.9 ± 0,5% of  wt), e mima il fenotipo del 
paziente. Gli studi condotti a livello proteico e gli esperimenti di 
immunofluorescenza indicano un meccanismo dominante-negativo 
particolarmente efficiente. La proteina deleta è sintetizzata in gran quantità 
ed è preferenzialmente processata e, attraverso il dominio “cysteine knot” 
correttamente codificato forma eterodimeri ed eterotetrameri con proteine 
VWF “wild type”. La compromissione del meccanismo di multimerizzazione 
è associata a una ridotta quantità di proteina VWF negli endosomi (“late 
endosomes”).
Il ruolo chiave degli eterodimeri come terminatori della multimerizzazione è 
inoltre supportato dall’effetto dovuto all’introduzione della mutazione 
C2773R nel costrutto deleto, la quale determina un difetto quantitativo in 
cui però i multimeri hanno dimensioni normali.
Utilizzando siRNA diretti contro il breakpoint è possibile silenziare 
selettivamente l’espressione della sola proteina VWF deleta, e ottenere un 
conseguente recupero dei livelli di VWF (VWF:CB 28.0 ± 3.3% of  wt). 
Questo approccio è un esempio per esplorare meccanismi di terapia genica 
mutazione-specifica in severe forme di malattia di von Willebrand, 
potenzialmente applicabili ad altre malattie causate da mutazioni con lo 
stesso effetto dominante-negativo.
70
Curriculum vitae et studiorium
The author of this thesis was born in Ferrara (Italy) on July 23, 1981, 
and accomplished secondary education at the high scool “Liceo 
Scientifico -A. Roiti-” in Ferrara. From 2000 to 2004 she was a student 
at the University of Ferrara, Biological science course, and graduated 
(bachelor degree -Laurea di  Primo Livello-) cum laude with a thesis 
entitled “Cellular microparticles: role in the coagulation” wrote under 
the supervision of Prof. Francesco Bernardi. From 2004 to 2006 she 
was student at the same University and finally obtained the 
Biomolecular and Cellular Science Master Degree (Laurea Specialistica) 
cum laude with an experimental work on von Willebrand factor. In 2007 
she entered a PhD program in Biochemistry, Molecular Biology and 
Biotecnology at the same University under the supervision of Dr. Mirko 
Pinotti  and Prof. Francesco Bernardi and she had the opportunity to 
study the molecular mechanism of a dominant-negative von Willebrand 
factor gene deletion and to propose a correction strategy based on 
siRNAs. Results described in this thesis were presented by the author 
at the last XXII Congress of the International Society on Thrombosis 
and Haemostasis, (Boston, USA -July 2009-) and she received the 
Young Investigator Award. Recently a manuscript containing most of 
these data has been submitted to Blood for publication.  
Acknowledgement
I am deeply grateful to Prof. Francesco Bernardi and 
Dr. Mirko Pinotti for opening my mind to science and 
sharing their knowledge to me supporting my work 
through the years. I also thank all my colleagues for 
their patience and for many valuable advices they 
have given to me. This thesis would never have been 
possible without the constant support and help of my 
precious family and of my good and sincere friends. 
71
